An Observational Study to Explore Clinical Characteristics of the Patients With T1 Non-small Cell Lung Cancer

May 18, 2018 updated by: Feng Jiang, Jiangsu Cancer Institute & Hospital

A Multi-centre Real-world Non-interventional Observational Study to Explore Clinical Characteristics of the Chinese Patients With T1 Non-small Cell Lung Cancer Complicated With Lymph Metastases

The real-world observational study was designed to explore the odd factors of lymph metastases in the patients with T1 non-small cell lung cancer, the effects of clinical characteristics on lymph metastases, and compare the differences in lymph metastases in the subgroups.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

The trial is a multi-centre, real-world non-interventional observational study. In the study, the patients with T1 non-small cell lung cancer enrolled in clinics from 2015 to 2017 were included via a retrospectively review method and the study data on patient demographic/tumor biological characteristics, and clinical treatments were collected to explore the clinical odd factors of lymph metastases, evaluate the effects of clinical characteristics on lymph metastases, and compare the differences in lymph metastases in the subgroups.

Study Type

Observational

Enrollment (Actual)

10885

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Beijing
      • Beijing, Beijing, China, 100029
        • China-Japan Friendship Hospital
      • Beijing, Beijing, China, 100853
        • China People's Liberation Army Hospital
    • Henan
      • Zhengzhou, Henan, China
        • Henan Cancer Hospital
      • Zhengzhou, Henan, China, 450003
        • Henan Cancer Hospital
    • Hubei
      • Wuhan, Hubei, China, 430030
        • Tongji Hospital Affiliated to Tongji Medical College, Huaxi Technology University
    • Jiangsu
      • Nanjing, Jiangsu, China, 210009
        • Jiangsu Cancer Institute and Hospital
    • Shaanxi
      • Xi'an, Shaanxi, China, 710000
        • Xi'an Tangdu Hospital
    • Shanghai
      • Shanghai, Shanghai, China, 200030
        • Shanghai Chest Hospital
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • West China Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310006
        • First Hospital Affiliated to Medical College, Zhejiang University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The eligible subjects are the Chinese T1 patients with non-small cell lung cancer complicated with lymph metastases

Description

Inclusion Criteria:

  • Patients who received surgeries from 2015 to 2017;
  • Pathologically diagnosed patients with T1 non-small cell lung cancer;

Exclusion Criteria:

- Patients with tumor treatments (including chemotherapies, radiotherapies, biological therapies, intervention therapies)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
NSCLC patients with lymph metastases
Pathologically diagnosed patients with T1 non-small cell lung cancer complicated with lymph metastases after surgeries
Surgeries

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of the patients with lymph metastases
Time Frame: 2015 - 2017
Percentages of the patients with lymph metastases categorised by patient demographic and tumor biological characteristics
2015 - 2017

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentages of N0/N1/N2/N3 patients
Time Frame: 2015 - 2017
Percentages of N0/N1/N2/N3 patients in the target population
2015 - 2017

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of N2 patients with lymph nodes
Time Frame: 2015 - 2017
Percentages of N2 patients with lymph nodes in N2 population
2015 - 2017
Percentage of patients with lymph metastases categorised by tumor baseline characteristics
Time Frame: 2015 - 2017
Percentage of patients with lymph metastases categorised by tumor baseline characteristics
2015 - 2017
Number of lymph nodes in N2 patients
Time Frame: 2015 - 2017
Number of lymph nodes in N2 patients categorised by tumor baseline characteristics
2015 - 2017
Percentage of patients with N2 skip metastases
Time Frame: 2015 - 2017
Percentage of patients with N2 skip metastases categorised by tumor baseline characteristics
2015 - 2017

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Lin Xu, Jiangsu Cancer Institute and Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2017

Primary Completion (Actual)

March 30, 2018

Study Completion (Actual)

March 30, 2018

Study Registration Dates

First Submitted

January 15, 2018

First Submitted That Met QC Criteria

January 22, 2018

First Posted (Actual)

January 29, 2018

Study Record Updates

Last Update Posted (Actual)

May 21, 2018

Last Update Submitted That Met QC Criteria

May 18, 2018

Last Verified

May 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Non Small Cell Lung Cancer

Clinical Trials on Surgeries

Subscribe